Femasys shares are trading higher after the company announced FDA clearance to continue enrollment in the final phase of its FINALE trial for FemBloc and entered agreements to issue $12M in notes and warrants, potentially raising up to $58M.

2025-11-03 21:35

Femasys宣佈FDA批准繼續參加FemBloc FINALEE試驗的最后階段，並達成發行1200萬美元票據和期權的協議，可能籌集高達5800萬美元的資金后，Femasys股價走高。